BioParity.UFO / UAP research

16 sources for “Government research funding”

Results

ReportS7680

FDA contract listing — selected Stanford award 75F40120C00176

U.S. Food and Drug Administration. fda.gov.

An FDA contract listing names Stanford University for 75F40120C00176, independently of the MaxFuse acknowledgement. The requirement concerns coronavirus research. Its wording differs from a later FDA presentation using the same identifier; the amendment or naming history remains unresolved. This supports a public institutional funding link, without establishing Nolan as the named principal investigator or a classified programme.

Partial root native PDF text and selected layout review
ArticleS7604

The Afterglow of a UAP Congressional Briefing

Avi Loeb. avi-loeb.medium.com. May 2, 2025.

Loeb recounts his May2025 congressional presentation and a Pentagon visit the previous day while advocating scientific UAP research. He allows that all UAPs might prove human-made. His funding proposal, technology speculation and planned instruments do not establish an awarded budget, recovered hardware or secret programme access.

Complete supplied public essay; original event and records missing
ArticleS7606

Congressional Briefing on UAP Science

Avi Loeb. avi-loeb.medium.com. April 28, 2025.

Loeb announces a planned May2025 congressional presentation, proposes new observations and offers to help analyze any government-held extrasolar information. That conditional offer originates with Loeb; it does not establish a government approach or access. Natural IM1 origins, funding contingencies and an all-human UAP outcome remain explicit possibilities.

Complete supplied public essay; planned event and original records qualified
PaperS7698

Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia

Jolanda Sarno, Pablo Domizi, Yuxuan Liu, Milton Merchant, Christina Bligaard Pedersen, Dorra Jedoui, Astraea Jager, Garry P. Nolan, Giuseppe Gaipa, Sean C. Bendall, Felice-Alessio Bava, Kara L. Davis. pmc.ncbi.nlm.nih.gov. May 22, 2023.

This leukemia paper reports laboratory, mouse and limited human-sample findings. The primary-sample combination result at 48 hours does not improve apoptosis beyond steroid alone; longer-culture observations use two selected specimens. Mouse survival findings require qualification for unequal toxicity censoring. It does not establish human combination-treatment efficacy. Nolan is credited with resources and clinical data alongside a coauthor, without a named funding award or government/UAP approach in this article.

Partial specialist supplied XML; method section and apparatus unreviewed

A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach